yip11 Antibody

What is IPO11 and what cellular functions does it perform?

IPO11 (Importin 11) is a member of the karyopherin/importin-beta family of transport receptors that mediate nucleocytoplasmic transport of protein and RNA cargoes . It functions as a nuclear import receptor, facilitating the movement of specific cargo proteins from the cytoplasm into the nucleus. The protein has a calculated molecular weight of 113 kDa and is typically observed at approximately 112 kDa in Western blot analyses . Its primary cellular localization is distributed between the cytoplasm and nucleus, reflecting its shuttling function between these compartments .

What types of IPO11 antibodies are available for research applications?

Research-grade IPO11 antibodies are available in several formats, with the most common being:

Most commercially available IPO11 antibodies are rabbit polyclonal antibodies generated using fusion proteins of human IPO11 as the immunogen . These antibodies typically undergo antigen affinity purification to enhance specificity and reduce background signals in experimental applications .

Which experimental systems show reliable IPO11 antibody reactivity?

According to validation studies, IPO11 antibodies show tested reactivity with human, mouse, and rat samples . Specifically:

• Positive Western blot detection: Human testis tissue

• Positive immunoprecipitation: Mouse testis tissue

• Positive immunohistochemistry: Human colon cancer tissue

• Positive immunofluorescence: HeLa cells

• Additional verified samples: K562 cells, human fetal brain, human tonsil, human breast cancer

Researchers should note that cross-reactivity profiles may vary between antibody clones and manufacturers.

What are the recommended dilutions and protocols for different IPO11 antibody applications?

Optimal dilutions for IPO11 antibody applications have been established through validation studies:

These values should be considered starting points; optimal conditions should be determined empirically for each experimental system . The signal intensity may vary depending on experimental conditions, sample quality, and antibody lot.

How can researchers validate the specificity of IPO11 antibodies for their experimental system?

A multi-modal approach is recommended for comprehensive validation of IPO11 antibodies:

• Knockout/knockdown validation: Test antibody specificity using IPO11 knockdown/knockout models. Published research has demonstrated this validation approach for IPO11 antibodies . The loss of signal in KO/KD samples confirms specificity.

• Mass spectrometry-based validation: Perform immunoprecipitation followed by mass spectrometry analysis to confirm IPO11 protein capture and identify potential cross-reactive proteins . This method assesses if the antibody can bind to its native antigen in cell lysates among thousands of other cellular components.

• Multiple antibody concordance: Compare signals obtained with different antibody clones targeting distinct IPO11 epitopes. Consistent patterns across different antibodies provide additional confidence in specificity.

• Western blot molecular weight validation: Confirm that the observed molecular weight matches the expected size of IPO11 (approximately 112-113 kDa) .

• Positive and negative tissue controls: Include tissues known to express or lack IPO11 in your experimental design to establish signal specificity .

How do different epitope binning strategies affect IPO11 antibody performance?

Epitope selection significantly impacts antibody performance, especially for complex proteins like IPO11:

Different epitope communities on a protein can yield antibodies with varying functional properties. For example, research on antibody generation campaigns has demonstrated that targeting diverse epitope communities can produce antibodies with different cross-species reactivities and functional characteristics .

For IPO11 antibodies, consider the following epitope-related factors:

• Cross-species conservation: Epitopes in conserved regions may yield antibodies with broader species reactivity (human, mouse, rat) .

• Domain-specific functions: Targeting functional domains of IPO11 might be important when studying specific aspects of importin biology.

• Accessibility in native conditions: Some epitopes may be masked in the native protein conformation, affecting antibody performance in non-denaturing applications like IP or IF.

• Epitope binning for paired antibody assays: When developing sandwich assays or competitive binding assays, antibodies targeting non-overlapping epitopes are required for capture and detection functions .

What controls should be included when using IPO11 antibodies in immunohistochemistry and immunofluorescence?

A robust control strategy is essential for reliable interpretation of IPO11 antibody staining:

• Positive tissue controls: Include tissues known to express IPO11, such as human testis, human colon cancer, or human tonsil samples .

• Negative controls:

  • Primary antibody omission

  • Isotype controls (matching IgG class, if using monoclonal antibodies)

  • Blocking peptide competition (pre-incubation of antibody with immunizing peptide)

• Fluorescence Minus One (FMO) controls: For multicolor flow cytometry experiments, include FMO controls where all fluorochromes except IPO11 are included to establish proper gating strategies .

• Antigen retrieval optimization: For IHC applications, compare different antigen retrieval methods:

  • TE buffer at pH 9.0 (preferred for IPO11)

  • Citrate buffer at pH 6.0 (alternative)

• Signal specificity validation: Confirm nuclear and cytoplasmic staining patterns consistent with IPO11's known localization .

How can researchers troubleshoot inconsistent Western blot results with IPO11 antibodies?

When encountering variability in Western blot results with IPO11 antibodies, consider the following methodological adjustments:

• Observed vs. expected molecular weight discrepancies: IPO11 has a calculated MW of 113 kDa but is observed at approximately 112 kDa . Significant deviations from this size may indicate:

  • Post-translational modifications

  • Protein degradation

  • Antibody cross-reactivity with other proteins

• Sample preparation optimization:

  • Include protease inhibitors to prevent degradation

  • Optimize lysis buffer composition (RIPA vs. NP-40 vs. modified buffers)

  • Test different protein denaturing conditions (temperature, SDS concentration)

• Transfer efficiency verification:

  • Use reversible total protein staining (Ponceau S) to confirm transfer

  • Adjust transfer conditions for high molecular weight proteins (113 kDa)

  • Consider extended transfer times or lower methanol concentrations

• Signal enhancement strategies:

  • Extended primary antibody incubation (overnight at 4°C)

  • Signal amplification systems (biotin-streptavidin)

  • Highly sensitive detection reagents

• Background reduction approaches:

  • Increase blocking time and concentration

  • Add 0.1-0.5% Tween-20 to antibody diluent

  • Consider alternative blockers (milk vs. BSA vs. commercial blockers)

How can researchers develop ultra-sensitive detection assays for low-abundance targets using IPO11 antibodies?

Development of ultra-sensitive assays requires strategic antibody pairing and platform selection:

The development of ultra-sensitive detection assays, as demonstrated in IL-11 target engagement studies, provides a methodological framework that can be applied to IPO11 detection :

• Antibody pair selection: Screen antibodies from distinct epitope communities to identify optimal capture and detection pairs. This requires:

  • Epitope binning to confirm non-overlapping binding sites

  • Affinity ranking to prioritize highest-affinity antibodies

  • Cross-reactivity assessment for species-specific applications

• Platform comparison for sensitivity optimization:

  • Enzyme-linked immunosorbent assay (ELISA): Baseline sensitivity

  • Meso Scale Discovery (MSD): Improved sensitivity over ELISA

  • Simoa HD-1 (digital ELISA): Ultra-sensitive detection

  • Simoa Planar Array (SP-X): Highest sensitivity with LLOQ potentially in the femtogram/mL range

• Assay format development:

  • "Free" target assay: Uses capture antibody with competing epitope to therapeutic antibody

  • "Total" target assay: Uses capture antibody with non-competing epitope

• Signal amplification strategies:

  • Multi-layer detection systems

  • Enzymatic signal amplification

  • Digital counting of single molecule events

How does IPO11 antibody performance compare in different tissue fixation protocols?

Fixation conditions significantly impact IPO11 antibody performance in immunohistochemistry and immunofluorescence applications:

• Formalin-fixed paraffin-embedded (FFPE) tissues:

  • Requires optimized antigen retrieval methods

  • Recommended protocols include TE buffer (pH 9.0) or citrate buffer (pH 6.0)

  • Extended retrieval times may be necessary for heavily fixed samples

• Frozen tissue sections:

  • Generally require shorter fixation (10-15 minutes in 4% paraformaldehyde)

  • May preserve some epitopes lost in FFPE processing

  • Can exhibit higher background with some antibodies

• Cell lines for immunofluorescence:

  • Validated in HeLa cells

  • Fixation optimization may be required for different cell types

  • Consider membrane permeabilization methods (Triton X-100 vs. methanol)

• Critical parameters for optimization:

  • Fixation duration

  • Fixative concentration

  • Post-fixation storage conditions

  • Antigen retrieval method and duration

  • Primary antibody incubation conditions

What strategies can improve immunoprecipitation efficiency with IPO11 antibodies?

Optimizing immunoprecipitation protocols for IPO11 requires careful consideration of several experimental parameters:

• Antibody amount optimization:

  • Recommended range: 0.5-4.0 μg per 1.0-3.0 mg of total protein lysate

  • Titrate to determine minimum effective concentration

• Lysis buffer selection:

  • Consider non-denaturing buffers to preserve protein-protein interactions

  • Include appropriate protease and phosphatase inhibitors

  • Adjust salt concentration to minimize non-specific interactions

• Pre-clearing strategy:

  • Pre-clear lysates with protein A/G beads to reduce non-specific binding

  • Include appropriate isotype control antibodies

• Incubation conditions:

  • Optimal temperature and duration (typically 4°C overnight)

  • Gentle agitation methods to prevent bead damage

• Washing optimization:

  • Buffer composition (salt concentration, detergent type/concentration)

  • Number and duration of washes

  • Temperature considerations

• Downstream validation:

  • Western blot confirmation of target enrichment

  • Mass spectrometry analysis to confirm specificity and identify interacting partners

  • Controls to distinguish specific from non-specific interactions

How can computational approaches enhance IPO11 antibody design and specificity prediction?

Recent computational methods can inform antibody design and predict specificity profiles:

• Biophysics-informed modeling approaches:

  • Machine learning models trained on experimental selection data can identify distinct binding modes associated with specific ligands

  • Computational disentanglement of multiple binding modes can inform antibody design

• Structure-conditioned antibody design:

  • The FvHallucinator framework and similar approaches enable generating antibody sequences conditioned on structural information

  • Such methods can create targeted CDR libraries that retain binding conformations

• Active learning strategies:

  • Active learning approaches can reduce the experimental data needed for accurate binding prediction by 35%

  • These methods iteratively select the most informative experiments to conduct

• Predictive features for specificity assessment:

  • CDR sequence analysis

  • Structural modeling of antibody-antigen interfaces

  • Physicochemical property mapping to binding characteristics

• Applications in IPO11 antibody research:

  • Design of antibodies with customized specificity profiles

  • Prediction of cross-reactivity with related importin family members

  • Optimization of affinity while maintaining specificity

How do knockout/knockdown validation studies affect interpretation of IPO11 antibody results?

Genetic validation approaches provide critical information for antibody specificity assessment:

• Complete validation strategy:

  • Genetic knockout (CRISPR-Cas9) provides the most definitive validation

  • siRNA or shRNA knockdown serves as an alternative approach

  • Compare signals between wild-type and KO/KD samples across applications

• Signal interpretation guidelines:

  • Complete signal loss in KO samples indicates high specificity

  • Partial signal reduction in KD samples should correlate with knockdown efficiency

  • Persistent signals in knockout samples suggest potential cross-reactivity

• Publication requirements:

  • Multiple journals now require genetic validation data for antibody-based studies

  • Documentation of validated KO models enhances research reproducibility

• Limitations and considerations:

  • Potential compensation by related proteins in knockout models

  • Differences between acute (siRNA) and chronic (CRISPR) depletion

  • Need to validate knockout/knockdown at both DNA and protein levels

• Antibody validation using KO/KD resources:

  • Published KO/KD validation data is available for some IPO11 antibodies

  • Consider collaborative approaches when KO/KD models are not readily available

What are the optimal storage and handling conditions for IPO11 antibodies?

Proper storage significantly impacts antibody performance and longevity:

• Recommended storage conditions:

  • Store at -20°C for long-term stability

  • Aliquot to avoid repeated freeze-thaw cycles

  • Stable for approximately one year after shipment under proper storage

• Buffer composition:

  • Typically supplied in PBS with 0.02% sodium azide and 50% glycerol at pH 7.3

  • Some preparations may contain 0.1% BSA as a stabilizer

• Transport considerations:

  • Typically shipped with ice packs

  • Store immediately at recommended temperature upon receipt

• Working solution preparation:

  • Dilute in appropriate buffer immediately before use

  • Avoid prolonged storage of diluted antibody

  • Include carrier protein (BSA) in working dilutions

• Stability monitoring:

  • Include positive controls in each experiment to monitor antibody performance

  • Document lot-to-lot variation through systematic validation

How can researchers improve the reproducibility of experiments using IPO11 antibodies?

Enhancing experimental reproducibility requires systematic approach to antibody-based methods:

• Detailed antibody reporting:

  • Document complete antibody information (catalog number, lot number, RRID)

  • Report dilutions, incubation conditions, and detection methods

  • Include validation data specific to the experimental context

• Standardized protocols:

  • Maintain consistent sample preparation methods

  • Standardize antibody dilution procedures

  • Use automated systems where possible to reduce variation

• Multiple detection methods:

  • Confirm findings using orthogonal approaches

  • Employ different antibody clones targeting distinct epitopes

  • Combine antibody-based with antibody-independent detection methods

• Quantitative controls:

  • Include calibration standards when possible

  • Normalize to appropriate reference proteins/genes

  • Implement quality control metrics for assay performance

• Statistical considerations:

  • Determine appropriate sample sizes through power analysis

  • Account for technical and biological replication

  • Apply appropriate statistical tests for the experimental design